Summary of the biomarkers across evidence levels in exMarker
Project progress (demo)
Evaluation Module 20%
Search Module 40%
Browse Module 60%
Server Construction 80%
Database Construction Complete!
Level of evidence classification system
evaluate exRNA biomarker for liquid biopsy (exMarker) is a comprehensive open resource for exploring non-invasive biomarkers for 31 types of human diseases, including cancers, precancerous lesions, cardiovascular diseases, and so on.
Currently, exMarker contains a large number of biomarkers for liquid biopsy across four molecular types, including DNA, RNA, protein, and metabolite. We manually curated 72 FDA-approved clinical biomarkers from the official website, and 1232 preclinical biomarkers from 745 research articles. Additionally, a large cohort of 4023 RNA-seq samples spanning seven specimen types was collected in exMarker, and approximately 45,000 RNA biomarker candidates were identified from these public high-throughput sequencing data in the field of liquid biopsy.
All biomarkers in exMarker are organized by a level of evidence classification system. Biomarkers in a specific disease type are assigned to one of four levels that are based on the strength of evidence to help users quickly evaluate the clinical potential of biomarkers of interest across different disease types.
exMarker released in June 2020
- Expanded to 31 types of human diseases, including cancers, precancerous lesions, cardiovascular diseases, and so on.
- Manually curated about 1300 biomarkers across four molecular types, including DNA, RNA, protein, and metabolite.
- Developed a level of evidence classification system.
- Identified 45,000 RNA biomarker candidates from published RNA-seq data of 4023 clinical samples spanning 7 specimen types.